German drugmaker Stada Arzneimittel (SAZ: Xetra) saw its share rise 1.35% to 48.26 euros in late morning trading today after it reported financial results, showing strong earnings growth.
Reported group sales showed a slight rise of 1% to 1,035 million euros. When effects on sales based on changes in the Group portfolio and currency effects are deducted, adjusted group salesincreased by 4% to 1,061 million euros.
Reported operating profit increased by 22% to 136.3 million euros in the first six months of 2016. Reported earnings before interest, taxes, depreciation and amortization (EBITDA) rose by 11% to 200.7 million euros. Reported net income increased by 53% to 82.0 million euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze